KRAS / RAS targeting: from platform to Phase 3
The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Gfh375 (VS-7375) NSCLC
@600
dose is 69% ORR and 94% DCR.
What's stated as 600 dose in presentation is all patients (doses) ORR of 58% and DCR of 89%. #AACR26
@DavidHongMD
Heat 10 · 8 likes · 0 replies · 2 reposts
Silvia Coma, Ian Smith, Cristina Caffarra Malvezzi, Clint A. Stalnecker, Emilia Berardelli, Enrico Patrucco, Fusheng Zhou, Channing Der, Chiara Ambrogio, David G. DeNardo, Jonathan A. Pachter
Read the abstract →Ryan D. Mouery, Kristina Drizyte-Miller, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der
Read the abstract →Brandon L. Mouery, Clint A. Stalnecker, Adrienne D. Cox, Silvia Coma, Jonathan A. Pachter, Channing J. Der
Read the abstract →Source: CrozrX · x.com